Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Viking Clinical Research

Neither a doctor nor a teaching hospital

Research payments

$124,390

112 payments

Through program year 2025, Viking Clinical Research is reported as receiving $124,390 in research payments, across 112 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $7,754 3
2024 Research $23,853 31
2023 Research $54,373 25
2022 Research $5,373 5
2021 Research $8,481 32
2020 Research $1,708 14
2019 Research $22,848 2

Breakdown

Who paid Research payments · program years 2019–2025
  1. Boehringer Ingelheim Pharmaceuticals, Inc. $63,611 8 payments
  2. ACADIA Pharmaceuticals Inc $18,615 1 payment
  3. Sage Therapeutics, Inc. $13,807 1 payment
  4. Boehringer Ingelheim Pharma GmbH & Co.KG $11,451 39 payments
  5. AbbVie, Inc. $7,754 3 payments
  6. H. Lundbeck A S $5,474 4 payments
  7. Sumitomo Pharma America, Inc. $2,194 48 payments
  8. Boehringer Ingelheim International GmbH $1,484 8 payments
Studies the money was for Research payments · program years 2019–2025
  1. Proof of concept and DRF in MDD $47,985 40 payments
  2. Acp-103-042 $18,615 1 payment
  3. Proof of Concept and DRF with TRPC4/5 inhibitor in MDD $17,936 2 payments
  4. A Phase 3, Open-Label, 1-Year Study of the Safety, Tolerability, and Need for Re-Treatment with SAGE-217 in Adult Subjects with Major Depressive Disorder $13,807 1 payment
  5. Proof of concept and DRF in BPD $10,625 13 payments
  6. Real-life Effectiveness of Vortioxetine in Depression RELIEVE $4,233 1 payment
  7. A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dose Study to Evaluate the Efficacy, Safety, and Tolerability of ABBV-932 as an Adjunct to Antidepressant Therapies in the Treatment of Subjects with Generalized Anxiety Disorder who have had an Inadequate Response to Antidepressant Therapies $3,759 1 payment
  8. Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Fixed-dose Study to Evaluate the Efficacy, Safety, and Tolerability of ABBV-932 in Subjects with Depressive Episodes Associated with Bipolar I or II Disorder $2,403 1 payment
  9. Multicenter, Open-label Study to Evaluate the Long-term Safety and Tolerability of ABBV-932 in Subjects with Depressive Episodes Associated with Bipolar I or II Disorder $1,593 1 payment
  10. A Phase 2/3, Randomized, Double-blind, Parallel Group, Placebo-controlled, Flexible-dose, Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults With Generalized Anxiety Disorder $1,344 28 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record